CoChat

Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells

Open access
Ranjan, Kishu, Waghela, Bhargav N, Vaidya, Foram U, Pathak, Chandramani · 2020 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Dysregulated expression of Fas-associated death domain (FADD) is associated with the impediment of various cellular pathways, including apoptosis and inflammation. The adequate cytosolic expression of FADD is critical to the regulation of cancer cell proliferation. Importantly, cancer cells devise mechanisms to suppress FADD expression and, in turn, escape from apoptosis signaling. Formulating strategies, for direct delivery of FADD proteins into cancer cells in a controlled manner, may represent a promising therapeutic approach in cancer therapy. We chemically conjugated purified FADD protein with cell permeable TAT (transactivator of transcription) peptide, to deliver in cancer cells. TAT-conjugated FADD protein internalized through the caveolar pathway of endocytosis and retained in the cytosol to augment cell death. Inside cancer cells, TAT-FADD rapidly constituted DISC (death inducing signaling complex) assembly, which in turn, instigate apoptosis signaling. The apoptotic competency of TAT-FADD showed comparable outcomes with the conventional apoptosis inducers. Notably, TAT-FADD mitigates constitutive NF-κB activation and associated downstream anti-apoptotic genes Bcl2, cFLIPL, RIP1, and cIAP2, independent of pro-cancerous TNF-α priming. In cancer cells, TAT-FADD suppresses the canonical NLRP3 inflammasome priming and restricts the processing and secretion of proinflammatory IL-1β. Our results demonstrate that TAT-mediated intracellular delivery of FADD protein can potentially recite apoptosis signaling with simultaneous regulation of anti-apoptotic and proinflammatory NF-κB signaling activation in cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21186890

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Human FADD protein conjugated with TAT peptide. (A) Schematic diagram showing the chemical conjugation of FADD protein (PDB ID-2GF5) with linker iodoacetamide and SMCC (4-MA) followed by TAT peptide. (B) In vitro protein interaction with purified His-tagged FADD and whole cell lysate (WCL) from HCT 116 cells, the immunoprecipitated (IP’ed) His-FADD interacts with binding partner cFLIPL protein, input lanes represent loading controls, as assessed by Western blot, molecular weight marker left to each blot. (C) The FT-IR analysis of TAT-FADD conjugate; inset box 1, 2, and 3 represent the corresponding peaks from the representative FT-IR spectrum. (D) In vitro protein interaction with His-taged TAT-FADD conjugate and whole cell lysate (WCL) from HCT 116 cells, the IP’ed His (TAT-FADD) interacts with cFLIPL protein, as assessed by Western blot, molecular weight marker left to each blot.
Figure 1 Human FADD protein conjugated with TAT peptide. (A) Schematic diagram showing the chemical conjugation of FADD protein (PDB ID-2GF5) with linker iodoacetamide and SMCC (4-MA) followed by TAT peptide. (B) In vitro protein interaction with purified His-tagged FADD and whole cell lysate (WCL) from HCT 116 cells, the immunoprecipitated (IP’ed) His-FADD interacts with binding partner cFLIPL protein, input lanes represent loading controls, as assessed by Western blot, molecular weight marker left to each blot. (C) The FT-IR analysis of TAT-FADD conjugate; inset box 1, 2, and 3 represent the corresponding peaks from the representative FT-IR spectrum. (D) In vitro protein interaction with His-taged TAT-FADD conjugate and whole cell lysate (WCL) from HCT 116 cells, the IP’ed His (TAT-FADD) interacts with cFLIPL protein, as assessed by Western blot, molecular weight marker left to each blot.CC BY · PubMed Central
Figure 2 TAT-FADD efficiently delivered inside the cells and retained in the cytoplasm. (A,B) HCT 116 cells were treated with TAT-FADD (TT-FD) at the mentioned concentrations for given time points and, (A) analysis of cell viability and (B) percent LDH release. (C–E) HCT 116 cells were transfected with GFP-Caveolin1 for 24 h followed by pre-incubation with MβCD (+MβCD; right panel) for 4 h, further cells were left untreated (0 h) or treated with 5 µM of TAT-FADD for 3–12 h, (C) the internalized TAT-FADD was immunostained with anti-His antibody (His tagged FADD) followed by counterstaining with DAPI and analyzed by confocal microscopy, representative of 25 cells from 3 different fields; scale bar 10 µm and (D) the % localization of TAT-FADD with GFP-Caveolin1 from ‘C’ was calculated with Image J software, (E) analysis of cell viability in the absence (−) and presence (+) of MβCD. (F) HCT 116 cells were treated with 5 µM of TAT-FADD for 3–12 h followed by analysis of cytosolic and nuclear fractions; GAPDH and histone H3 was used as cytosolic and nuclear protein markers, respectively, molecular weight marker left to each blot. The 0 h represents untreated cells. In (A), significance compared between non-treated (NT) and TAT-FADD treated cells; in (B), significance compared between non-treated (0 h) and TAT-FADD treated cells; in (D,E), significance is compared between unprimed (-MβCD; white bars) and primed (+MβCD; black bars) cells treated with TAT-FADD. h, hours; ns, non-significant. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.
Figure 2 TAT-FADD efficiently delivered inside the cells and retained in the cytoplasm. (A,B) HCT 116 cells were treated with TAT-FADD (TT-FD) at the mentioned concentrations for given time points and, (A) analysis of cell viability and (B) percent LDH release. (C–E) HCT 116 cells were transfected with GFP-Caveolin1 for 24 h followed by pre-incubation with MβCD (+MβCD; right panel) for 4 h, further cells were left untreated (0 h) or treated with 5 µM of TAT-FADD for 3–12 h, (C) the internalized TAT-FADD was immunostained with anti-His antibody (His tagged FADD) followed by counterstaining with DAPI and analyzed by confocal microscopy, representative of 25 cells from 3 different fields; scale bar 10 µm and (D) the % localization of TAT-FADD with GFP-Caveolin1 from ‘C’ was calculated with Image J software, (E) analysis of cell viability in the absence (−) and presence (+) of MβCD. (F) HCT 116 cells were treated with 5 µM of TAT-FADD for 3–12 h followed by analysis of cytosolic and nuclear fractions; GAPDH and histone H3 was used as cytosolic and nuclear protein markers, respectively, molecular weight marker left to each blot. The 0 h represents untreated cells. In (A), significance compared between non-treated (NT) and TAT-FADD treated cells; in (B), significance compared between non-treated (0 h) and TAT-FADD treated cells; in (D,E), significance is compared between unprimed (-MβCD; white bars) and primed (+MβCD; black bars) cells treated with TAT-FADD. h, hours; ns, non-significant. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.CC BY · PubMed Central
Figure 3 TAT-FADD constituted DISC assembly and induces apoptosis signaling. (A) HCT 116, HeLa, and MCF-7 cells were treated with 5 µM of TAT-FADD for 3–12 h, the His-tagged TAT-FADD was immunoprecipated (IP’ed) using anti-His antibody followed by analysis of DISC assembly proteins procaspase-8 (Pro-C-8) and cFLIPL, molecular weight marker left to each blot. (B–F) HCT 116 cells were treated with 5 µM of TAT-FADD for 3–12 h followed by analysis of (B) % apoptotic death by flow cytometry, (C) measurement of caspase-8 (C-8) activity, (D) analysis of apoptosis regulatory proteins, molecular weight marker left to each blot, (E) % change in MMP and (F) measurement of caspase-3 activity. (G,H) HCT 116 cells were transfected with pcDNA3-cFLIPL for 48 h (lane 2 and 5), primed with TNF-α (10 ng/mL) for 12 h (lane 3 and 6) followed by treatment with 5 µM of TAT-FADD for 6 h (lane 4, 5 & 6), (G) analysis of cFLIPL expression by Western blot, molecular weight marker left to each blot and (H) % apoptotic death by a Tali™ image-based cytometer; control represents vector transfected and non-TNF-α-primed cells. In (B,C,E,F), significance compared between non-treated (represents as 0 h) and TAT-FADD-treated cells; in H, significance compared between non-treated (white bars) and TAT-FADD-treated cells (black bars); control in white bar represents a vector transfected and non-TNF-α-primed cells. h, hours; clv, cleaved; MMP, mitochondrial membrane potential. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.
Figure 3 TAT-FADD constituted DISC assembly and induces apoptosis signaling. (A) HCT 116, HeLa, and MCF-7 cells were treated with 5 µM of TAT-FADD for 3–12 h, the His-tagged TAT-FADD was immunoprecipated (IP’ed) using anti-His antibody followed by analysis of DISC assembly proteins procaspase-8 (Pro-C-8) and cFLIPL, molecular weight marker left to each blot. (B–F) HCT 116 cells were treated with 5 µM of TAT-FADD for 3–12 h followed by analysis of (B) % apoptotic death by flow cytometry, (C) measurement of caspase-8 (C-8) activity, (D) analysis of apoptosis regulatory proteins, molecular weight marker left to each blot, (E) % change in MMP and (F) measurement of caspase-3 activity. (G,H) HCT 116 cells were transfected with pcDNA3-cFLIPL for 48 h (lane 2 and 5), primed with TNF-α (10 ng/mL) for 12 h (lane 3 and 6) followed by treatment with 5 µM of TAT-FADD for 6 h (lane 4, 5 & 6), (G) analysis of cFLIPL expression by Western blot, molecular weight marker left to each blot and (H) % apoptotic death by a Tali™ image-based cytometer; control represents vector transfected and non-TNF-α-primed cells. In (B,C,E,F), significance compared between non-treated (represents as 0 h) and TAT-FADD-treated cells; in H, significance compared between non-treated (white bars) and TAT-FADD-treated cells (black bars); control in white bar represents a vector transfected and non-TNF-α-primed cells. h, hours; clv, cleaved; MMP, mitochondrial membrane potential. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.CC BY · PubMed Central
Figure 4 TAT-FADD’s pro-apoptotic effect is compared with conventional apoptosis inducers. (A) Schematic diagram representing the target site of proposed apoptosis inducers. (B–E) HCT 116 cells were treated with CD 95L (200 ng/mL), TNF-α (50 ng/mL), etoposide (50 µM), HA14-1 (5 µM), protein translational inhibitor cycloheximide (CHX, 5 µg/mL), and TAT-FADD (5 µM) alone for the mentioned time points, (B) The bright field images of cells counterstained with DAPI, post treatments, representative of 150 cells from 3 independent fields, scale bar 5 µm, (C) % apoptotic death by a Tali™ image-based cytometer, (D) % change in MMP and (E) expression of Procaspase-7 and cleavage of PARP by Western blot analysis, molecular weight marker left to each blot. In (C,D), significance compared between non-treated (0 h, white bars) and treated cells (black bars). h, hours; clv, cleaved; CD95-R, CD95 receptor; TNF-R, TNF receptor; MMP, mitochondrial membrane potential. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.
Figure 4 TAT-FADD’s pro-apoptotic effect is compared with conventional apoptosis inducers. (A) Schematic diagram representing the target site of proposed apoptosis inducers. (B–E) HCT 116 cells were treated with CD 95L (200 ng/mL), TNF-α (50 ng/mL), etoposide (50 µM), HA14-1 (5 µM), protein translational inhibitor cycloheximide (CHX, 5 µg/mL), and TAT-FADD (5 µM) alone for the mentioned time points, (B) The bright field images of cells counterstained with DAPI, post treatments, representative of 150 cells from 3 independent fields, scale bar 5 µm, (C) % apoptotic death by a Tali™ image-based cytometer, (D) % change in MMP and (E) expression of Procaspase-7 and cleavage of PARP by Western blot analysis, molecular weight marker left to each blot. In (C,D), significance compared between non-treated (0 h, white bars) and treated cells (black bars). h, hours; clv, cleaved; CD95-R, CD95 receptor; TNF-R, TNF receptor; MMP, mitochondrial membrane potential. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.CC BY · PubMed Central
Figure 5 TAT-FADD suppresses constitutive and TNF-α-primed NF-κB activation in cancer cells. (A–C) HCT 116 cells were treated with 5 µM of TAT-FADD for 3–12 h and (A) NF-κB luciferase activity, (B) mRNA expression of cFLIPL and cIAP2, and (C) expression of NF-κB signaling protein, molecular weight marker left to each blot. (D–F) MCF-7 cells were treated with 5 µM of TAT-FADD for 3–12 h and (D) NF-κB luciferase activity, (E) mRNA expression of cFLIPL and cIAP2, and (F) expression of NF-κB signaling protein, molecular weight marker left to each blot. Control represents untreated cells. (G–J) HCT 116 cells were primed with TNF-α (10 ng/mL) for 12 h followed by treatment of 5 µM TAT-FADD for 6 h and (G) NF-κB luciferase activity, (H,I) mRNA expression of (H) Bcl2 and (I) cFLIPL, cIAP2 and RIP1, (J) TRAF2 was immunoprecipitated (IP) followed by binding analysis of ubiquitin, cIAP2, and RIP1 protein by Western blot, molecular weight marker left to each blot. Control represents untreated cells. In (A,B,D,E), significance compared between non-treated (represents as 0 h) and TAT-FADD-treated cells; in (G–I), significance is compared between non-treated (white bars) and TNF-α-primed cells (gray bars); and between TNF-α-primed cells and TAT-FADD-treated cells (black and dark gray bars respectively). h, hours; WCL, whole cell lysate. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.
Figure 5 TAT-FADD suppresses constitutive and TNF-α-primed NF-κB activation in cancer cells. (A–C) HCT 116 cells were treated with 5 µM of TAT-FADD for 3–12 h and (A) NF-κB luciferase activity, (B) mRNA expression of cFLIPL and cIAP2, and (C) expression of NF-κB signaling protein, molecular weight marker left to each blot. (D–F) MCF-7 cells were treated with 5 µM of TAT-FADD for 3–12 h and (D) NF-κB luciferase activity, (E) mRNA expression of cFLIPL and cIAP2, and (F) expression of NF-κB signaling protein, molecular weight marker left to each blot. Control represents untreated cells. (G–J) HCT 116 cells were primed with TNF-α (10 ng/mL) for 12 h followed by treatment of 5 µM TAT-FADD for 6 h and (G) NF-κB luciferase activity, (H,I) mRNA expression of (H) Bcl2 and (I) cFLIPL, cIAP2 and RIP1, (J) TRAF2 was immunoprecipitated (IP) followed by binding analysis of ubiquitin, cIAP2, and RIP1 protein by Western blot, molecular weight marker left to each blot. Control represents untreated cells. In (A,B,D,E), significance compared between non-treated (represents as 0 h) and TAT-FADD-treated cells; in (G–I), significance is compared between non-treated (white bars) and TNF-α-primed cells (gray bars); and between TNF-α-primed cells and TAT-FADD-treated cells (black and dark gray bars respectively). h, hours; WCL, whole cell lysate. Mean ± SD; * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001.CC BY · PubMed Central
Figure 6 TAT-FADD suppresses proinflammatory activation of IL-1β. (A,B) HCT116 cells were treated with 5 µM of TAT-FADD for 3–12 h, (A) mRNA expression of NLRP3, procaspase-1, and pro-IL-1β, and (B) endogenous expression of NLRP3, procaspase-1 (pro Casp-1), and pro IL-1β by Western blot, molecular weight marker left to each blot. The 0 h represents untreated cells. (C–E) HCT 116 cells were primed with LPS (100 ng/mL, 12 h) and ATP (5 mM, 2 h) followed by treatment with 5 µM of TAT-FADD for 3–12 h and (C) mRNA expression of pro-IL-1β, (D) expression levels of endogenous NLRP3, procaspase-1, and pro IL-1β by Western blot, molecular weight marker left to each blot, and (E) levels of matured IL-1β was measured by ELISA assay from the culture supernatant. In (C,E) (white bar) and in (D) (lane 1), it represents un-primed and non-treated cells for 12 h taken as controls. In (A), significance is compared between non-treated (represents as 0 h) and TAT-FADD-treated cells; in (C), significance compared between non-treated (white bars) and LPS with ATP-primed cells (gray bars); and between LPS with ATP primed cells treated with TAT-FADD treated cells (black & dark gray bars respectively). h, hours. Mean ± SD; ** p ≤ 0.01 and *** p ≤ 0.001.
Figure 6 TAT-FADD suppresses proinflammatory activation of IL-1β. (A,B) HCT116 cells were treated with 5 µM of TAT-FADD for 3–12 h, (A) mRNA expression of NLRP3, procaspase-1, and pro-IL-1β, and (B) endogenous expression of NLRP3, procaspase-1 (pro Casp-1), and pro IL-1β by Western blot, molecular weight marker left to each blot. The 0 h represents untreated cells. (C–E) HCT 116 cells were primed with LPS (100 ng/mL, 12 h) and ATP (5 mM, 2 h) followed by treatment with 5 µM of TAT-FADD for 3–12 h and (C) mRNA expression of pro-IL-1β, (D) expression levels of endogenous NLRP3, procaspase-1, and pro IL-1β by Western blot, molecular weight marker left to each blot, and (E) levels of matured IL-1β was measured by ELISA assay from the culture supernatant. In (C,E) (white bar) and in (D) (lane 1), it represents un-primed and non-treated cells for 12 h taken as controls. In (A), significance is compared between non-treated (represents as 0 h) and TAT-FADD-treated cells; in (C), significance compared between non-treated (white bars) and LPS with ATP-primed cells (gray bars); and between LPS with ATP primed cells treated with TAT-FADD treated cells (black & dark gray bars respectively). h, hours. Mean ± SD; ** p ≤ 0.01 and *** p ≤ 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 24

Metadata

Authors
Ranjan, K., Waghela, B. N., Vaidya, F. U., & Pathak, C.
Affiliations
Indian Institute of Advanced Research (IN)
Corresponding author
Pathak, Chandramani
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-09-19
Volume
21
Issue
18
Pages
6890
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3087422657
Cited by
24
References
70
Citations by year
2025: 4 · 2024: 6 · 2023: 3 · 2022: 8 · 2021: 3
FWCI
1.14
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Department of Biotechnology, Ministry of Science and Technology, India (6242/P60/RGCB/PMD/DBT/CMPK/2015)
  • Department of Science & Technology (EMR/2016/002574)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
FADD, cell-penetrating peptides, apoptosis, NF-κB signaling, NLRP3 inflammasome, IL-1β, death-inducing signaling complex, caveolar endocytosis, anti-apoptotic proteins, cancer therapy, protein delivery
MeSH terms
RAW 264.7 Cells, Animals, Gene Expression Regulation, HeLa Cells, Humans, Neoplasm Proteins, Neoplasms, Apoptosis, HCT116 Cells, Mice, Fas-Associated Death Domain Protein, Hep G2 Cells, HEK293 Cells, Cell-Penetrating Peptides, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells. https://app.cochat.ai/papers/10.3390/ijms21186890
The paper
Ranjan, K., Waghela, B. N., Vaidya, F. U., & Pathak, C. (2020). Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21186890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.